Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on November 27, 2007
JNCI Journal of the National Cancer Institute 2007 99(23):1746-1748; doi:10.1093/jnci/djm258
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
99/23/1746    most recent
djm258v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

READERS BEWARE?

Trend Toward Noninferiority Trials May Mean More Difficult Interpretation of Trial Results

Rabiya S. Tuma

The first 150 words of the full text of this article appear below.

The number of noninferiority trials in oncology is on the rise, and the trend will probably continue as the number of approved drugs increases. Experts warn that this shift from testing superiority to noninferiority will make interpreting trial results more difficult. Some researchers even question the value of dedicating limited resources just to show that a new drug is no worse than one already in use.

Most oncology trials remain superiority trials, which are designed to establish that a new treatment is outright better than the existing therapy. The increased use of noninferiority trials, which are designed to establish that the new therapy is no worse than the existing one, means that researchers and clinicians need to become more familiar with the approach, one that experts warn is not always intuitive—or properly used.

There is a perception among some clinicians and researchers that pharmaceutical companies use noninferiority trials as a . . . [Full Text of this Article]

Choosing the Right Design

Getting to the Statistics

Is Noninferiority the Question?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?